Early Kidney Damage Detection in Diabetes Using Urine Albumin-Creatinine Ratio: A Diagnostic Yield Study
Article Sidebar
Main Article Content
Abstract
Background: Diabetic kidney disease may begin silently, and serum creatinine can remain normal during early renal injury. Urine albumin-creatinine ratio is a practical screening test for detecting early albuminuria before routine renal function markers become abnormal. Objective: To determine the diagnostic yield of urine albumin-creatinine ratio for detecting microalbuminuria among adult diabetic patients with normal serum creatinine and to assess its association with diabetes duration and blood pressure control. Methods: This diagnostic yield study was conducted at a tertiary-care hospital in Bahawalpur, Punjab, Pakistan. A total of 180 adult diabetic patients with normal serum creatinine were included through consecutive sampling. Patients with known chronic kidney disease, raised serum creatinine, urinary tract infection, pregnancy, fever, heart failure, or acute severe illness were excluded. Microalbuminuria was defined as urine albumin-creatinine ratio of 30–300 mg/g. Associations with diabetes duration and blood pressure control were assessed using chi-square tests. Results: Microalbuminuria was detected in 62 of 180 patients, giving a diagnostic yield of 34.4% with a 95% confidence interval of 27.9–41.6%. Microalbuminuria increased with diabetes duration, from 20.7% in patients with duration below 5 years to 50.9% in those above 10 years. It was also more frequent in patients with uncontrolled blood pressure than controlled blood pressure, 48.6% versus 24.5%. Both associations were statistically significant. Conclusion: Urine albumin-creatinine ratio identified early albuminuria in a substantial proportion of diabetic patients with normal serum creatinine. Longer diabetes duration and uncontrolled blood pressure were associated with higher microalbuminuria frequency
Article Details
Issue
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
References
1. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: global and regional diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. doi:10.1016/j.diabres.2021.109119.
2. Basit A, Fawwad A, Qureshi H, Shera AS; NDSP Members. Prevalence of diabetes, pre-diabetes and associated risk factors: second National Diabetes Survey of Pakistan, 2016–2017. BMJ Open. 2018;8(8):e020961. doi:10.1136/bmjopen-2017-020961.
3. Akhtar S, Nasir JA, Abbas T, Sarwar A. Diabetes in Pakistan: a systematic review and meta-analysis. Pak J Med Sci. 2019;35(4):1173-1178. doi:10.12669/pjms.35.4.194.
4. Hasan SU, Siddiqui MR. Nationwide prevalence of type 2 diabetes mellitus and pre-diabetes in Pakistan: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2024;216:111815. doi:10.1016/j.diabres.2024.111815.
5. Stevens PE, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, et al. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4 Suppl):S117-S314. doi:10.1016/j.kint.2023.10.018.
6. American Diabetes Association Professional Practice Committee. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1). doi:10.2337/dc26-S011.
7. Kidney Disease: Improving Global Outcomes Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102(5 Suppl):S1-S127. doi:10.1016/j.kint.2022.06.007.
8. de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association and Kidney Disease: Improving Global Outcomes. Diabetes Care. 2022;45(12):3075-3090. doi:10.2337/dci22-0027.
9. Christofides EA, Desai N. Optimal early diagnosis and monitoring of diabetic kidney disease in type 2 diabetes mellitus: addressing the barriers to albuminuria testing. J Prim Care Community Health. 2021;12:21501327211003683. doi:10.1177/21501327211003683.
10. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014;37(10):2864-2883. doi:10.2337/dc14-1296.
11. Norris KC, Smoyer KE, Rolland C, Van der Vaart J, Grubb EB. Albuminuria, serum creatinine, and estimated glomerular filtration rate as predictors of cardio-renal outcomes in patients with type 2 diabetes mellitus and kidney disease: a systematic literature review. BMC Nephrol. 2018;19(1):36. doi:10.1186/s12882-018-0821-9.
12. Fox CS, Matsushita K, Woodward M, Bilo HJG, Chalmers J, Lambers Heerspink HJ, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380(9854):1662-1673. doi:10.1016/S0140-6736(12)61350-6.
13. Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis. Lancet Diabetes Endocrinol. 2015;3(7):514-525. doi:10.1016/S2213-8587(15)00040-6.
14. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310(6):356-360. doi:10.1056/NEJM198402093100605.
15. Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014. JAMA. 2016;316(6):602-610. doi:10.1001/jama.2016.10924.
16. Thomas MC, Brownlee M, Susztak K, Sharma K, Jandeleit-Dahm KAM, Zoungas S, et al. Diabetic kidney disease. Nat Rev Dis Primers. 2015;1:15018. doi:10.1038/nrdp.2015.18.
17. Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032-2045. doi:10.2215/CJN.11491116.
18. Wu AYT, Kong NCT, de Leon FA, Pan CY, Tai TY, Yeung VTF, et al. An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence Study. Diabetologia. 2005;48(1):17-26. doi:10.1007/s00125-004-1599-9.
19. Kanakamani J, Ammini AC, Gupta N, Dwivedi SN. Prevalence of microalbuminuria among patients with type 2 diabetes mellitus: a hospital-based study from North India. Diabetes Technol Ther. 2010;12(2):161-166. doi:10.1089/dia.2009.0133.
20. Sana MA, Chaudhry M, Malik A, Iqbal N, Zakiuddin A, Abdullah M. Prevalence of microalbuminuria in type 2 diabetes mellitus. Cureus. 2020;12(12):e12318. doi:10.7759/cureus.12318.
21. Khan TM, Nawaz FK, Karim MS, Shafique Z, Anwar MS, Usman O. Incidence of microalbuminuria and factors affecting it in patients with type 2 diabetes mellitus. Cureus. 2022;14(7):e27294. doi:10.7759/cureus.27294.
22. Asghar S, Asghar S, Mahmood T, Bukhari SMH, Mumtaz MH, Rasheed A. Microalbuminuria as the tip of iceberg in type 2 diabetes mellitus: prevalence, risk factors, and associated diabetic complications. Cureus. 2023;15(8):e43190. doi:10.7759/cureus.43190.
23. Latif H, Iqbal A, Rathore R, Butt NF. Correlation between serum uric acid level and microalbuminuria in type-2 diabetic nephropathy. Pak J Med Sci. 2017;33(6):1371-1375. doi:10.12669/pjms.336.13224.
24. Zeb S, Babar B, Bibi S, Shah MA. Correlation of uric acid with microalbuminuria in type-2 diabetic patients with normal creatinine. Pak J Med Sci. 2024;40(5):951-955. doi:10.12669/pjms.40.5.8208.
25. Qamar N, Mehdi RF, Ekram S, Irfan Z, Sundus S, Rehman A, et al. Association of glycated hemoglobin and microalbuminuria with renal function parameters in type 2 diabetic patients. Pakistan Journal of Health Sciences. 2025;6(5):02-06. doi:10.54393/pjhs.v6i5.2988.